Acquisition
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
Jazz Pharmaceuticals
PR-M05-21-005-999May 06, 2021
Study Results
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
Nice Insight
PR-M03-19-NI-085Mar 29, 2019
FDA Approval
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jazz Pharmaceuticals
PR-M11-18-NI-006Nov 02, 2018
FDA Approval
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jazz Pharmaceuticals
PR-M10-18-NI-100Oct 30, 2018